CA2923426A1 - Formulations for cgrp receptor antagonists - Google Patents
Formulations for cgrp receptor antagonists Download PDFInfo
- Publication number
- CA2923426A1 CA2923426A1 CA2923426A CA2923426A CA2923426A1 CA 2923426 A1 CA2923426 A1 CA 2923426A1 CA 2923426 A CA2923426 A CA 2923426A CA 2923426 A CA2923426 A CA 2923426A CA 2923426 A1 CA2923426 A1 CA 2923426A1
- Authority
- CA
- Canada
- Prior art keywords
- liquid pharmaceutical
- pharmaceutical composition
- composition according
- oxo
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361878183P | 2013-09-16 | 2013-09-16 | |
| US61/878,183 | 2013-09-16 | ||
| PCT/US2014/055132 WO2015038736A2 (en) | 2013-09-16 | 2014-09-11 | Formulations for cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2923426A1 true CA2923426A1 (en) | 2015-03-19 |
Family
ID=52666511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2923426A Pending CA2923426A1 (en) | 2013-09-16 | 2014-09-11 | Formulations for cgrp receptor antagonists |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160220552A1 (https=) |
| EP (2) | EP3046923A4 (https=) |
| JP (1) | JP6612234B2 (https=) |
| KR (3) | KR20210153745A (https=) |
| CN (2) | CN105531275B (https=) |
| AU (1) | AU2014318741B2 (https=) |
| BR (1) | BR112016005589B8 (https=) |
| CA (1) | CA2923426A1 (https=) |
| IL (1) | IL244356B (https=) |
| MX (1) | MX384611B (https=) |
| RU (1) | RU2690006C2 (https=) |
| SA (1) | SA516370737B1 (https=) |
| WO (1) | WO2015038736A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI487706B (zh) * | 2010-11-12 | 2015-06-11 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| JP6491669B2 (ja) | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｇｒｐ活性化合物の錠剤製剤 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20210128724A1 (en) * | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2023049920A1 (en) | 2021-09-27 | 2023-03-30 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| CN119350337A (zh) * | 2024-12-24 | 2025-01-24 | 药康众拓(北京)医药科技有限公司 | 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739393B2 (en) * | 1998-03-19 | 2001-10-11 | Merck Sharp & Dohme Corp. | Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations |
| GB9815801D0 (en) * | 1998-07-21 | 1998-09-16 | Merck & Co Inc | Liquid polymeric compositions for controlled released bioactive substances |
| ITRM20020357A1 (it) * | 2002-07-03 | 2004-01-05 | Foscama Biomed Chim Farma | Composizione liquida per la somministrazione orale di lorazepam. |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| EP2063708A2 (en) * | 2006-09-08 | 2009-06-03 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| TWI487706B (zh) | 2010-11-12 | 2015-06-11 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
-
2014
- 2014-09-11 KR KR1020217040059A patent/KR20210153745A/ko not_active Ceased
- 2014-09-11 MX MX2016003394A patent/MX384611B/es unknown
- 2014-09-11 KR KR1020227025748A patent/KR20220108207A/ko not_active Ceased
- 2014-09-11 EP EP14844555.4A patent/EP3046923A4/en not_active Withdrawn
- 2014-09-11 US US15/021,471 patent/US20160220552A1/en not_active Abandoned
- 2014-09-11 KR KR1020167006505A patent/KR102337994B1/ko active Active
- 2014-09-11 WO PCT/US2014/055132 patent/WO2015038736A2/en not_active Ceased
- 2014-09-11 RU RU2016114537A patent/RU2690006C2/ru active
- 2014-09-11 JP JP2016542091A patent/JP6612234B2/ja active Active
- 2014-09-11 CA CA2923426A patent/CA2923426A1/en active Pending
- 2014-09-11 CN CN201480050553.6A patent/CN105531275B/zh not_active Expired - Fee Related
- 2014-09-11 EP EP21171525.5A patent/EP3915561A1/en active Pending
- 2014-09-11 CN CN202011381004.0A patent/CN112545981A/zh active Pending
- 2014-09-11 AU AU2014318741A patent/AU2014318741B2/en active Active
- 2014-09-11 BR BR112016005589A patent/BR112016005589B8/pt active IP Right Grant
-
2016
- 2016-02-29 IL IL244356A patent/IL244356B/en active IP Right Grant
- 2016-03-14 SA SA516370737A patent/SA516370737B1/ar unknown
-
2018
- 2018-09-10 US US16/125,924 patent/US20190070161A1/en not_active Abandoned
-
2020
- 2020-12-07 US US17/114,169 patent/US20210330660A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210153745A (ko) | 2021-12-17 |
| NZ717327A (en) | 2021-10-29 |
| JP6612234B2 (ja) | 2019-11-27 |
| CN112545981A (zh) | 2021-03-26 |
| IL244356B (en) | 2020-09-30 |
| US20190070161A1 (en) | 2019-03-07 |
| KR20220108207A (ko) | 2022-08-02 |
| WO2015038736A2 (en) | 2015-03-19 |
| RU2016114537A (ru) | 2017-10-23 |
| KR20160055149A (ko) | 2016-05-17 |
| CN105531275B (zh) | 2020-12-18 |
| BR112016005589B1 (pt) | 2022-12-06 |
| EP3046923A2 (en) | 2016-07-27 |
| BR112016005589A8 (pt) | 2018-02-06 |
| AU2014318741A1 (en) | 2016-03-10 |
| BR112016005589B8 (pt) | 2023-04-18 |
| US20210330660A1 (en) | 2021-10-28 |
| SA516370737B1 (ar) | 2021-05-27 |
| WO2015038736A3 (en) | 2015-11-12 |
| RU2016114537A3 (https=) | 2018-07-04 |
| IL244356A0 (en) | 2016-04-21 |
| EP3915561A1 (en) | 2021-12-01 |
| RU2690006C2 (ru) | 2019-05-30 |
| MX384611B (es) | 2025-03-14 |
| CN105531275A (zh) | 2016-04-27 |
| JP2016530316A (ja) | 2016-09-29 |
| KR102337994B1 (ko) | 2021-12-13 |
| AU2014318741B2 (en) | 2018-12-06 |
| MX2016003394A (es) | 2016-10-28 |
| US20160220552A1 (en) | 2016-08-04 |
| EP3046923A4 (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014318741B2 (en) | Formulations for CGRP receptor antagonists | |
| AU2016385362B2 (en) | Long acting injectable formulations | |
| JP2002526424A (ja) | パクリタクセル含有医薬組成物 | |
| US20100087392A1 (en) | Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics | |
| AU2022298186B2 (en) | Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof | |
| ITMI20002717A1 (it) | Composizioni farmaceutiche | |
| NZ717327B2 (en) | Formulations for cgrp receptor antagonists | |
| JP2001316265A (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| EP2874624B1 (en) | Injectable antibiotic formulations and their methods of use | |
| CA3222421C (en) | Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof | |
| NL2028762B1 (en) | Micelle-generating formulations for enhanced bioavailability | |
| KR100896375B1 (ko) | 주사용 의약 제제 | |
| JP6665057B2 (ja) | ボルテゾミブを含有する医薬製剤 | |
| EP2874623B1 (en) | Injectable antibiotic formulations and their methods of use | |
| NZ613138B2 (en) | Injectable antibiotic formulations and their methods of use | |
| NZ613240B2 (en) | Injectable antibiotic formulations and their methods of use | |
| WO2014108791A1 (en) | Injectable composition containing chlorothiazide | |
| NZ613240A (en) | Injectable antibiotic formulations and their methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190813 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240808 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT Effective date: 20241112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20241121 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20250711 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250711 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250711 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250711 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |